Questcor Pharmaceuticals (NASDAQ:QCOR) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report issued on Monday, AnalystRatingsNetwork reports. The firm currently has a $70.70 price target on the stock. Zacks‘ price objective indicates a potential upside of 19.59% from the company’s current price. Other equities research analysts have also recently […]
Questcor Pharmaceuticals Upgraded to Outperform at Zacks (QCOR) is a post from: Zolmax
The post Questcor Pharmaceuticals Upgraded to Outperform at Zacks (QCOR) appeared first on Zolmax.